PTGX - Protagonist Therapeutics, Inc

QQQ $ 623.31 $ 0.00 (0 %)

DIA $ 469.77 $ 0.00 (0 %)

SPY $ 676.03 $ 0.00 (0 %)

TLT $ 89.90 $ 0.00 (0 %)

GLD $ 367.64 $ 0.00 (0 %)

Previous Close

$ 75.95

Open

$ 78.62

Bid

$ 75.00 x 5

Ask

$ 80.90 x 20

Day's Range

-- - --

52 Week Range

$ 33.31 - $ 93.25

Volume

1,041,567

Average Volume

Market Cap

4.72B

Beta (5Y Monthly)

$ 0.90

PE Ratio (TTM)

$ 90.80

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	08-06-2025	06-30-2025	10-Q
2	05-06-2025	03-31-2025	10-Q
3	02-21-2025	12-31-2024	10-K
4	11-07-2024	09-30-2024	10-Q
5	08-06-2024	06-30-2024	10-Q
6	05-07-2024	03-31-2024	10-Q
7	02-27-2024	12-31-2023	10-K
8	11-02-2023	09-30-2023	10-Q
9	08-03-2023	06-30-2023	10-Q
10	05-04-2023	03-31-2023	10-Q
11	03-15-2023	12-31-2022	10-K
12	11-08-2022	09-30-2022	10-Q
13	08-04-2022	06-30-2022	10-Q
14	05-05-2022	03-31-2022	10-Q
15	02-28-2022	12-31-2021	10-K
16	11-03-2021	09-30-2021	10-Q
17	08-04-2021	06-30-2021	10-Q
18	05-04-2021	03-31-2021	10-Q
19	03-10-2021	12-31-2020	10-K
20	11-04-2020	09-30-2020	10-Q
21	08-06-2020	06-30-2020	10-Q
22	05-07-2020	03-31-2020	10-Q
23	03-10-2020	12-31-2019	10-K
24	11-06-2019	09-30-2019	10-Q
25	08-07-2019	06-30-2019	10-Q
26	05-08-2019	03-31-2019	10-Q
27	03-12-2019	12-31-2018	10-K
28	11-06-2018	09-30-2018	10-Q
29	08-07-2018	06-30-2018	10-Q
30	05-09-2018	03-31-2018	10-Q
31	03-07-2018	12-31-2017	10-K
32	11-07-2017	09-30-2017	10-Q
33	08-08-2017	06-30-2017	10-Q
34	05-10-2017	03-31-2017	10-Q
35	03-07-2017	12-31-2016	10-K
36	11-14-2016	09-30-2016	10-Q
37	09-15-2016	06-30-2016	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Truist Securities Maintains Buy on Protago...
10/28/2025 16:00:56

Truist Securities analyst Srikripa Devarakonda maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Buy and raises the pr...

Wedbush Maintains Outperform on Protagonis...
10/28/2025 13:11:44

Wedbush analyst Yun Zhong maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Outperform and raises the price target fro...

What 7 Analyst Ratings Have To Say About P...
10/28/2025 11:44:49

BTIG Reiterates Buy on Protagonist Therape...
10/28/2025 09:23:17

BTIG analyst Julian Harrison reiterates Protagonist Therapeutics (NASDAQ:PTGX) with a Buy and maintains $82 price target.

Protagonist Therapeutics Announces New Dat...
10/27/2025 11:41:43

Icotrokinra demonstrated clinically meaningful outcomes at Week 28 in the Phase 2b ANTHEM-UC study in ulcerative colitis, with ...

Citigroup Maintains Buy on Protagonist The...
10/17/2025 15:29:08

Citigroup analyst Geoff Meacham maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Buy and raises the price target from...

johnson--johnson-to-separate-orthopedics-business-boosts-annual-sales-outlook

Johnson & Johnson To Separate Orthopedics ...
10/14/2025 12:51:28

Johnson & Johnson beats Q3 estimates, raises 2025 sales guidance, and announces plans to spin off its $9.2 billion orthoped...

johnson--johnson-q3-preview-with-stock-near-all-time-highs-heres-what-to-watch

Johnson & Johnson Q3 Preview: With Stock N...
10/13/2025 16:27:44

Johnson & Johnson stock trades near all-time highs with an upcoming Q3 earnings report acting as the next catalyst.

fda-adds-new-warning-for-johnson--johnsons-cancer-cell-therapy

FDA Adds New Warning For Johnson & Johnson...
10/13/2025 14:30:41

FDA updates Johnson & Johnson's Carvykti label to warn of rare immune-related enterocolitis while reaffirming the thera...

12 Health Care Stocks Moving In Friday's I...
10/10/2025 17:06:47

johnson--johnson-in-talks-to-acquire-protagonist-therapeutics-report

Johnson & Johnson In Talks To Acquire Prot...
10/10/2025 17:06:05

Johnson & Johnson is in talks to buy Protagonist Therapeutics in a deal that could expand its immunology and cancer drug po...

Protagonist Therapeutics Shares Resume Trade
10/10/2025 15:33:28

Protagonist Therapeutics Shares Halted On ...
10/10/2025 15:15:37

'Johnson & Johnson In Talks To Buy Protago...
10/10/2025 15:15:04

https://www.wsj.com/health/pharma/johnson-johnson-in-talks-to-buy-protagonist-therapeutics-38e0b69d

5 Analysts Assess Protagonist Therapeutics...
10/08/2025 12:01:55

HC Wainwright & Co. Reiterates Buy on Prot...
10/08/2025 10:21:42

HC Wainwright & Co. analyst Douglas Tsao reiterates Protagonist Therapeutics (NASDAQ:PTGX) with a Buy and maintains $80 ...

Protagonist Therapeutics' Oral IL-23 Block...
10/07/2025 12:12:09

Icotrokinra met the primary endpoint of clinical response at all three doses, with 36.5% of patients treated achieving endoscop...

Demystifying Protagonist Therapeutics: Ins...
09/17/2025 20:01:41

johnson--johnson-protagonist-study-shows-superior-skin-clearance-in-psoriasis-trials

Johnson & Johnson, Protagonist Study Shows...
09/17/2025 19:15:33

Johnson & Johnson and Protagonist Therapeutics announced new data from their Phase 3 studies to treat severe plaque psoriasis.

HC Wainwright & Co. Reiterates Buy on Prot...
09/17/2025 15:43:39

HC Wainwright & Co. analyst Douglas Tsao reiterates Protagonist Therapeutics (NASDAQ:PTGX) with a Buy and maintains $80 ...